Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2021
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 FusionsIgor Odintsov, Allan J W Lui, Whitney J Sisso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung CancerKen Suzawa, Michael Offin, Daniel Lu, et al.
Disease Models & Mechanisms|December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulationTakuo Hayashi, Igor Odintsov, Roger S Smith, et al.
Cancer Discovery|February 18, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapyChristopher A Febres-Aldana, Morana Vojnic, Igor Odintsov, et al.
Cancer Discovery|February 9, 2022
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene RearrangementsAlison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, et al.
Cancer Discovery|April 4, 2018
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged CancersAlexander Drilon, Romel Somwar, Biju P Mangatt, et al.
Disease Models & Mechanisms|November 29, 2021
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signalingRoger S Smith, Igor Odintsov, Zebing Liu, et al.
Pageof 4